Life Sciences partner Scott Lassman provides insight on several timely issues shaping the biosimilars landscape, including:
- Drug Pricing Legislation
- Changes to the FDA Under Scott Gottlieb, MD
- Industry Takeaways From Allergan’s Patent Transfer
- Follow-On Biologics and the “Regulatory Dead Zone”
- Products to Be Regulated as Biologics by 2020
- Follow-On Products Versus Biosimilars
- Waiving the Single Shared REMS Requirement
- REMS Programs and Biosimilar Therapies
- The BPCIA Versus Hatch-Waxman Litigation
- FDA and the BPCIA
- Trends in Congressional Concern Over Drug Pricing
- The Challenge of Drug Importation